CAS: 120737-59-9; Tert-Butyl 3-Methylpiperazine-1-Carboxylate

该化合物是一种化学化合物,其特点是其管子子子核心,这是一个由六人组成的环,内含两个氮原子."N-Boc"的称谓表明存在一个与氮原子之一相连的三丁基氧碳基(Boc)保护组,该组通常用于有机合成,以保护氨."2-甲基"是指与管子环第二碳相连的甲基组,它影响化合物的性能和电子特性.该化合物一般是白色至非白固体的,在有机溶剂中溶解.它经常用于合成各种生物活性化合物的制药化学,特别是在开发药物候选物时.由于存在该组,可以在温和条件下有选择地进行非保护,从而有利于进一步的功能化.总体而言,4-N-Boc-2-M乙基-乙基子素是有机合成和药用化学的多功能中间体.

结构式图片

相似化合物

147081-29-6 163765-44-4 313657-42-0

物理性质

MSDS等安全信息

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号24424-99-5 二碳酸二叔丁酯 | CAS号109-07-9 2-甲基哌嗪 | CAS号73371-96-7 2-[[(tert-butox... | CAS号58632-95-4 2-(叔-丁氧基碳酰胺)-2-苯乙腈 | CAS号34619-03-9 碳酸二叔丁酯 | CAS号25057-77-6 1,2-二甲基哌嗪 | CAS号621-84-1 氨基甲酸苄酯 | CAS号741287-32-1 3,4-二甲基哌嗪-1-羧酸叔丁酯

合成工艺路线路线简述

  • 合成目标产物 4-N-Boc-2-Methyl-Piperazine 主要起始原料 Di-Tert-Butyl Dicarbonate And 2-Methylpiperazine
  • (文献来源)合成步骤主要原料 Di-Tert-Butyl Dicarbonate 和 2-Methylpiperazine
📜2-甲基哌嗪 以 四氢呋喃,水 用作溶剂,化学反应生成1-Boc-3-甲基哌嗪
参考文献:Cyanophenyl Derivatives
标题:Cyanophenyl Derivatives

海关参考信息

专利信息


专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-2022363662-A1
优先权日:2021-04-20
标题 :Compounds as lxr agonists
发明人：PUJALA BRAHMAM; SATHE BALAJI DASHRATH; DANODIA ABHINANDAN; GUPTA ASHU; SONI SANJEEV; KUMAR VIVEK; ANSARI AMANTULLAH; KHAN FARHA; SARKAR ARINDAM; PAYGHAN PAVAN V
权利人:INTEGRAL BIOSCIENCES PRIVATED LTD
摘要:The present invention generally discloses compounds having LXR (the liver X receptor) agonistic activity, to the use of such compounds in the treatment of various disorders such as proliferative disorders, Alzheimer's disease, inflammatory diseases, and diseases characterized by defects in cholesterol and lipid metabolism. Specifically, the present invention discloses compound of formula (IA) which exhibit LXR agonist activity, specifically to LXRβ. The invention also discloses method of synthesis of said compounds, method of using said compounds, pharmaceutical compositions comprising said compounds and method of using thereof.

专利号:US-2023192682-A1
优先权日:2019-11-14
标题:Improved synthesis of kras g12c inhibitor compound

专利号:US-2023192681-A1
优先权日:2019-11-14
标 题 :Improved synthesis of kras g12c inhibitor compound

专利号:WO-2020102730-A1
优先权日:2018-11-16
标 题:Improved synthesis of key intermediate of kras g12c inhibitor compound

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

⚠️全国化工行业净网倡议书
📋制造商识别码
📖 海关编码查询
📝MSDS生成器

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献


参考文献:10.1134/s1068162025603313
摘要:Goyal R, Gupta S, Sharma PC, Chopra H. Design, Synthesis, In Vitro Hydrolysis and Biological Evaluation of Antioxidant-Conjugated Mutual Prodrugs of Naproxen. Russ J Bioorg Chem. 2026 Jan 29;52(1). doi: 10.1134/s1068162025603313.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知